Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?

Increasingly sophisticated therapies for chemical castration dominate first-line treatments locally advanced prostate cancer. However, androgen deprivation therapy (ADT) offers little prospect of a cure, as resistant tumors emerge rather rapidly, normally within 30 months. Cells have multiple mechanisms resistance to even the most drug regimes, and both tumor cell heterogeneity in cancer salvage pathways result castration-resistant disease related genetically original hormone-naive The timing death after ADT are not well understood, off-target effects long-term due functional extra-prostatic expression receptor protein now increasingly being recorded. Our knowledge how these widely used fail at biological level patients is deficient. In this review, I will discuss whether there pre-existing drug-resistant cells mass, or induced/selected by ADT. Equally, what origin resistance, does it differ from treatment-naïve differentiation dedifferentiation? Conflicting evidence also emerges studies range systems species employed answer key question. It only improving our understanding aspect treatment simply devising another new means inhibition that we can improve patient outcomes.